The efficacy and safety of datopotamab deruxtecan (Dato-DXd) in advanced solid tumors: a systematic review and meta-analysis
Jie Huang, Ting Huang, Junhua Guo, Keke Hu, Heran Zhou · 2025
Read The efficacy and safety of datopotamab deruxtecan (Dato-DXd) in advanced solid tumors: a systematic review and meta-analysis by Jie Huang, Ting Huang, Junhua Guo, Keke Hu, Heran Zhou (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12751586.txt.
Description
Jie Huang and four co-authors present a 2025 review pooling trial evidence on a targeted drug for advanced solid tumors. The drug couples an antibody, which homes to a surface protein common on tumor cells, with a poison payload it ferries inside. It recently won approval for a common breast cancer type.
The team searched four databases for studies of the drug in advanced cancers, through early 2025. They pooled response rates, survival figures, and side effect data across trials. Early phase results looked promising, but single trials are small and vary. A pooled read gives clinicians a firmer sense of who benefits and what harms to watch for.
Catalog record
| CREATOR | Jie Huang, Ting Huang, Junhua Guo, Keke Hu, Heran Zhou |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |